New Study Demonstrates Lunit SCOPE IO's Effectiveness to Pre

New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24.

Related Keywords

Italy , France , Seoul , Soult Ukpyolsi , South Korea , Brandon Suh , , Mayo Clinic , Clinical Oncology , Biliary Tract Cancer , Tumor Microenvironment , Scope , Osmo , Unit , Lunit Scope , Non Small Cell Lung Cancer ,

© 2025 Vimarsana